Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
NCT02589236 is registered in ClinicalTrials.gov with Nivalis Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor
- Lead sponsor
- Nivalis Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2015
- Completion date
- December 31, 2016
- Enrollment
- 138 (actual)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.